La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Alkem Laboratories Résultats passés
Passé contrôle des critères 5/6
Alkem Laboratories a connu une croissance annuelle moyenne de ses bénéfices de 6.8%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en hausse à 15.4% par an. Les revenus ont augmenté de en hausse à un taux moyen de 10.9% par an. Le rendement des capitaux propres de Alkem Laboratories est 19.4% et ses marges nettes sont de 16.1%.
Informations clés
6.8%
Taux de croissance des bénéfices
6.8%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 17.5% |
| Taux de croissance des recettes | 10.9% |
| Rendement des fonds propres | 19.4% |
| Marge nette | 16.1% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Aug 13
Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 27Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00
Jul 13Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jun 27Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00
Jun 13Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Jun 01Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)
May 22Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets
Feb 13Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects
Jan 17We Think Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt With Ease
Dec 27Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?
Sep 14Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Aug 02Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Jul 07Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
May 22We Think Alkem Laboratories (NSE:ALKEM) Can Stay On Top Of Its Debt
Mar 27Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
Dec 26These 4 Measures Indicate That Alkem Laboratories (NSE:ALKEM) Is Using Debt Reasonably Well
Sep 20Alkem Laboratories' (NSE:ALKEM) Dividend Is Being Reduced To ₹4.00
Jul 27Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 13Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Jun 11Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
May 23Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Mar 06Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
Feb 21Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Feb 08Should You Be Adding Alkem Laboratories (NSE:ALKEM) To Your Watchlist Today?
Jan 09Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Nov 30Here's Why Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt Responsibly
Nov 17I Built A List Of Growing Companies And Alkem Laboratories (NSE:ALKEM) Made The Cut
Sep 07Ventilation des recettes et des dépenses
Comment Alkem Laboratories gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 127,317 | 20,542 | 30,675 | 0 |
| 31 Mar 24 | 126,676 | 17,958 | 30,329 | 0 |
| 31 Dec 23 | 126,344 | 15,732 | 30,394 | 0 |
| 30 Sep 23 | 123,514 | 14,329 | 29,926 | 0 |
| 30 Jun 23 | 119,906 | 11,433 | 30,081 | 0 |
| 31 Mar 23 | 115,993 | 9,842 | 29,726 | 0 |
| 31 Dec 22 | 111,805 | 10,208 | 27,081 | 0 |
| 30 Sep 22 | 107,586 | 10,917 | 26,536 | 0 |
| 30 Jun 22 | 104,792 | 13,051 | 25,772 | 0 |
| 31 Mar 22 | 106,342 | 16,456 | 25,769 | 0 |
| 31 Dec 21 | 103,425 | 17,780 | 22,660 | 0 |
| 30 Sep 21 | 100,416 | 17,033 | 22,048 | 0 |
| 30 Jun 21 | 96,044 | 16,311 | 21,183 | 0 |
| 31 Mar 21 | 88,650 | 15,850 | 19,807 | 0 |
| 31 Dec 20 | 87,218 | 15,338 | 21,217 | 0 |
| 30 Sep 20 | 85,971 | 14,648 | 21,076 | 0 |
| 30 Jun 20 | 84,984 | 13,636 | 20,892 | 0 |
| 31 Mar 20 | 83,444 | 11,271 | 20,853 | 0 |
| 31 Dec 19 | 81,484 | 11,057 | 20,347 | 0 |
| 30 Sep 19 | 78,929 | 9,262 | 19,855 | 0 |
| 30 Jun 19 | 75,478 | 8,098 | 19,237 | 0 |
| 31 Mar 19 | 73,572 | 7,605 | 18,728 | 0 |
| 31 Dec 18 | 70,157 | 6,602 | 17,762 | 0 |
| 30 Sep 18 | 68,318 | 6,293 | 17,412 | 0 |
| 30 Jun 18 | 67,788 | 6,955 | 17,212 | 0 |
| 31 Mar 18 | 63,918 | 6,309 | 16,555 | 0 |
| 31 Dec 17 | 60,044 | 7,009 | 15,102 | 0 |
| 30 Sep 17 | 57,285 | 7,626 | 14,699 | 0 |
| 30 Jun 17 | 55,019 | 7,248 | 14,245 | 0 |
| 31 Mar 17 | 56,875 | 8,920 | 13,910 | 0 |
| 31 Dec 16 | 56,933 | 7,732 | 13,497 | 0 |
| 30 Sep 16 | 54,992 | 7,267 | 12,977 | 0 |
| 30 Jun 16 | 52,419 | 7,108 | 9,430 | 0 |
| 31 Mar 16 | 49,248 | 7,416 | 11,699 | 0 |
| 31 Dec 15 | 47,975 | 8,189 | 15,267 | 220 |
| 30 Sep 15 | 44,556 | 7,227 | 15,252 | 291 |
| 30 Jun 15 | 40,459 | 5,781 | 11,940 | 150 |
| 31 Mar 15 | 37,434 | 3,916 | 9,032 | 0 |
| 31 Mar 14 | 31,191 | 4,353 | 10,466 | 210 |
Des revenus de qualité: ALKEM a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de ALKEM (16.1%) sont supérieures à celles de l'année dernière (9.5%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de ALKEM ont augmenté de 6.8% par an au cours des 5 dernières années.
Accélération de la croissance: La croissance des bénéfices de ALKEM au cours de l'année écoulée ( 79.7% ) dépasse sa moyenne sur 5 ans ( 6.8% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices ALKEM au cours de l'année écoulée ( 79.7% ) a dépassé celle du secteur Pharmaceuticals 19.3%.
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de ALKEM ( 19.4% ) est considéré comme faible.